We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
BioNTech SE | NASDAQ:BNTX | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
2.29 | 2.55% | 92.24 | 90.29 | 93.21 | 92.40 | 90.68 | 90.75 | 561,842 | 01:00:00 |
MAINZ, GERMANY, January 5, 2021 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO and Co-founder Ugur Sahin, M.D., will present a corporate overview and update at the virtual 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021, at 10.50am ET.
A live webcast of the presentation will be available via the “Events & Presentations” page in the Investor Relations section on the Company’s website at https://biontech.de/. The replay of the webcast will be archived on the Company’s website for 30 days following the conference.
About BioNTech Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.
BioNTech Contacts:
Media RelationsJasmina Alatovic+49 89 62 81 75 46 Media@biontech.de
Investor RelationsSylke Maas, Ph.D.+49 (0)6131 9084 1074Investors@biontech.de
1 Year BioNTech Chart |
1 Month BioNTech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions